Author:
Bi Vivian,Jawa Vibha,Joubert Marisa K.,Kaliyaperumal Arunan,Eakin Catherine,Richmond Karen,Pan Oscar,Sun Jilin,Hokom Martha,Goletz Theresa J.,Wypych Jette,Zhou Lei,Kerwin Bruce A.,Narhi Linda O.,Arora Taruna
Reference46 articles.
1. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products;Koren;J Immunol Methods,2008
2. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies;Ponce;Regul Toxicol Pharmacol,2009
3. CBER, Draft Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products (February 2013) can be accessed at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf.
4. EMEA, Guideline on Strategies to Identify and Mitigate Risks for First-inhuman Clinical Trials with Investigational Medicinal Products (July 2007) can be accessed at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf.
5. Prediction of immunogenicity of therapeutic proteins: Validity of computational tools;Bryson;BioDrugs,2010
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献